In Attraction-04 phase II trial, the same authors evaluated the role of combining nivolumab with chemotherapy in advanced or recurrent unresectable HER2-negative gastric or GEJ adenocarcinomas [49]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.